Combination of Cholecalciferol and Rivastigmine Improves Cognitive Dysfunction and Reduces Inflammation in STZ Induced Alzheimer's Model Experimentally in Rats

Egyptian Journal of Basic and Clinical Pharmacology

Amany N. Ibrahim¹  Magdy I. Attallah²  Reham Abdelrahman Elnaggar³ 

[1] Department of Clinical Pharmacology, Faculty of Medicine, Benha University, Benha, Qalubiya, Egypt;Department of Medical Pharmacology, Faculty of Medicine, Cairo University, Kasr Alainy, Cairo, Egypt;Department of Pharmacology and Toxicology, Faculty of Pharmacy, Misr University for Science and Technology (MUST), 6th of October City, Giza, Egypt;

关键词: Alzheimer's;    ICV-STZ;    vitamin D3;    rivastigmine;    TNF-α;   

DOI  :  10.11131/2018/101369

来源: DOAJ

【 摘 要 】

Background. Alzheimer's disease (AD) is a multifactorial disease, and the mechanisms underlying its pathogenesis are complex. Several studies have implicated amyloid β (Aβ) accumulation, hyperphosphorylated tau, oxidative stress, metal dysregulation, mitochondrial dysfunction, and inflammatory response as major interconnecting networks leading to neuronal and synaptic degeneration. Aim. The present study was designed to evaluate the neuroprotective effects of cholecalciferol (vitamin D3) and rivastigmine, alone and in combination, on the progression of Alzheimer's disease induced by intracerebroventricular administration of streptozotocin and possible anti-inflammatory mechanisms of action. Materials and Methods. Adult male albino rats were divided randomly into five groups: group I acts as control. In group II (Alzheimer's group), Alzheimer's was induced by single bilateral intracerebroventricular injection of STZ (3mg/kg). Group III (cholecalciferol treated group) rats received cholecalciferol (42 IU/kg, s.c.) for 21 days immediately after ICV-STZ injection. Group IV (rivastigmine-treated group) Alzheimer's rats received rivastigmine (1.5 mg/kg, s.c.) for a period of 21 days immediately after ICV-STZ injection. Group V (rivastigmine + cholecalciferol) rats received rivastigmine plus cholecalciferol for 21 days immediately after ICV-STZ injection. Cognitive impairment was evaluated by Morris Water Maze test. Serum and brain pro-inflammatory mediators (TNF-α and IL-1β) were measured. Also, brain level of acetylcholine was measured. Moreover, serum and brain levels of amyloid beta peptide were evaluated. Results. After 21 days of induction of Alzheimer's, the ICV-STZ induced significant impairment of memory and declined cognition as manifested by the increased latency period in Morris Water Maze test. Serum and brain levels of TNF-α, IL-1β, and amyloid peptide were significantly increased. On the other hand, brain acetylcholine level was significantly decreased compared with the control group. All these parameters were significantly improved by rivastigmine alone and in combination with vitamin D3. These results clearly pointed to the pivotal role of rivastigmine and vitamin D3 in STZ induced Alzheimer's in rats by improving inflammatory status. Conclusion. The present study concludes the neuroprotective effect of rivastigmine and vitamin D3 in Alzheimer's disease rats by reducing inflammatory mediators (TNF-α and IL-1β) and amyloid β peptide and improving acetylcholine levels in brain.

【 授权许可】

Unknown